ESLAW — Estrella Immunopharma, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1844417 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -7,496,223 -7,382,080 1,671,026 92,458 15,642,730
Jun 2026 0 — -2,084,247 -2,306,339 1,824,681 146,670 9,256,014
Mar 2026 0 — -2,292,064 -2,292,064 3,657,198 1,927,404 8,927,494
Dec 2025 0 — -613,199 -613,174 3,176,975 1,384,302 13,543,033

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-9,383,567
Investing CF
—
Financing CF
$8,213,643
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
—
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-41,589,218
Inventory
—
Receivables
$178,011
ST Investments
—
EBIT TTM
$-9,790,659
Pretax Income TTM
$-10,012,751
Interest Exp TTM
—
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -13,062,674 -13,063,512 3,176,975 13,543,033 -10,366,058 -1,785,679
Jun 2024 0 -7,310,098 -7,311,723 4,454,189 180,701 4,273,488 -16,068,306
Jun 2023 0 -11,114,402 -11,114,402 3,028,399 14,770,949 -11,742,550 -1,336,121
Jun 2022 0 -1,685,347 -1,685,347 4,921,666 5,961,509 -1,039,843 -1,442,028

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-10,012,726
OpCashFlow TTM
—
Assets (Latest)
$1,824,681
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
AMGN AMGEN INC $247.70B $457.93 —
GILD GILEAD SCIENCES, INC. $211.18B $170.26 —
MRNA Moderna, Inc. $82.56B $206.80 —
ARGX ARGENX SE $58.92B $947.52 —
BIIB BIOGEN INC. $37.07B $250.79 —

News headlines (Yahoo Finance, 1h cache)

Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional
2026-11-16 13:00 · Yahoo
Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
2026-10-26 12:00 · Yahoo
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
2026-10-15 22:45 · Yahoo
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
2026-10-14 20:15 · Yahoo
ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial
2026-08-26 12:42 · Yahoo
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
2026-08-11 12:00 · Yahoo
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
2026-08-03 12:00 · Yahoo
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
2026-07-29 12:00 · Yahoo
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
2026-07-24 12:00 · Yahoo
ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?
2026-07-14 10:22 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.